Xlife Sciences AG (SWX:XLS)
20.40
-0.40 (-1.92%)
At close: Oct 21, 2025
Xlife Sciences AG Revenue
Xlife Sciences AG had revenue of 354.32K CHF in the half year ending June 30, 2025, with 1.82% growth. This brings the company's revenue in the last twelve months to 839.38K, down -15.24% year-over-year. In the year 2024, Xlife Sciences AG had annual revenue of 834.88K, down -15.54%.
Revenue (ttm)
839.38K
Revenue Growth
-15.24%
P/S Ratio
140.17
Revenue / Employee
49.38K
Employees
17
Market Cap
117.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 834.88K | -153.56K | -15.54% |
Dec 31, 2023 | 988.44K | -39.54K | -3.85% |
Dec 31, 2022 | 1.03M | 221.91K | 27.53% |
Dec 31, 2021 | 806.07K | 409.26K | 103.14% |
Dec 31, 2020 | 396.81K | -118.02K | -22.92% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Sandoz Group AG | 8.42B |
Alcon | 7.97B |
Lonza Group AG | 7.09B |
Galenica AG | 4.03B |
Sonova Holding AG | 3.87B |
Galderma Group AG | 3.73B |